Display options
Cite
Jazedje T, Ribeiro AL, Pellati M, et al. Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches. Stem Cells Int. 2015;2015:796215doi: 10.1155/2015/796215.
Jazedje, T., Ribeiro, A. L., Pellati, M., de Siqueira Bueno, H. M., Nagata, G., Trierveiler, M., Rodrigues, E. G., & Zatz, M. (2015). Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches. Stem cells international, 2015796215. https://doi.org/10.1155/2015/796215
Jazedje, T, et al. "Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches." Stem cells international vol. 2015 (2015): 796215. doi: https://doi.org/10.1155/2015/796215
Jazedje T, Ribeiro AL, Pellati M, de Siqueira Bueno HM, Nagata G, Trierveiler M, Rodrigues EG, Zatz M. Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches. Stem Cells Int. 2015;2015:796215. doi: 10.1155/2015/796215. Epub 2015 Apr 27. PMID: 26000020; PMCID: PMC4427122.
Copy Download .nbib Format: NLM
Share it on

Stem Cells Int. 2015;2015:796215. doi: 10.1155/2015/796215. Epub 2015 Apr 27.

Human Mesenchymal Stromal Cells Transplantation May Enhance or Inhibit 4T1 Murine Breast Adenocarcinoma through Different Approaches.

Stem cells international

T Jazedje, A L Ribeiro, M Pellati, H M de Siqueira Bueno, G Nagata, M Trierveiler, E G Rodrigues, M Zatz

Affiliations

  1. Human Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil ; Laboratory of Cancer Immunobiology, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), 04023-062 São Paulo, SP, Brazil.
  2. Laboratory of Cancer Immunobiology, Department of Microbiology, Immunology and Parasitology, Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP), 04023-062 São Paulo, SP, Brazil.
  3. Human Genome and Stem-Cell Center (HUG-CELL), Institute of Bioscience, University of São Paulo, 05508-090 São Paulo, SP, Brazil.
  4. Stomatology Department, Faculty of Dentistry, University of São Paulo, 05508-000 São Paulo, SP, Brazil.

PMID: 26000020 PMCID: PMC4427122 DOI: 10.1155/2015/796215

Abstract

The use of Mesenchymal Stromal Cells (MSCs) aiming to treat cancer has shown very contradictory results. In an attempt to clarify the contradictory results reported in the literature and the possible role of human fallopian tube Mesenchymal Stromal Cells (htMSCs) against breast cancer, the aim of this study was to evaluate the clinical effect of htMSCs in murine mammary adenocarcinoma using two different approaches: (1) coinjections of htMSCs and 4T1 murine tumor cell lineage and (2) injections of htMSCs in mice at the initial stage of mammary adenocarcinoma development. Coinjected animals had a more severe course of the disease and a reduced survival, while tumor-bearing animals treated with 2 intraperitoneal injections of 10(6) htMSCs showed significantly reduced tumor growth and increased lifespan as compared with control animals. Coculture of htMSCs and 4T1 tumor cells revealed an increase in IL-8 and MCP-1 and decreased VEGF production. For the first time, we show that MSCs isolated from a single source and donor when injected in the same animal model and tumor can lead to opposite results depending on the experimental protocol. Also, our results demonstrated that htMSCs can have an inhibitory effect on the development of murine mammary adenocarcinoma.

References

  1. Tissue Eng Part A. 2009 Feb;15(2):427-35 - PubMed
  2. Nurse Pract. 2011 Dec 16;36(12):20-6; quiz 7 - PubMed
  3. Mol Cancer Res. 2005 Jan;3(1):1-13 - PubMed
  4. Clin Exp Immunol. 2011 Apr;164(1):1-8 - PubMed
  5. Front Oncol. 2014 Apr 02;4:70 - PubMed
  6. Stem Cells. 2008 Jan;26(1):146-50 - PubMed
  7. J Exp Med. 2006 May 15;203(5):1235-47 - PubMed
  8. Int J Cancer. 2010 Nov 15;127(10):2323-33 - PubMed
  9. Biomed Rep. 2013 Jul;1(4):539-544 - PubMed
  10. Cell Cycle. 2011 May 1;10(9):1370-3 - PubMed
  11. PLoS One. 2009 Jul 17;4(7):e6278 - PubMed
  12. Stem Cells. 2011 Jan;29(1):11-9 - PubMed
  13. Stem Cell Rev. 2012 Jun;8(2):355-62 - PubMed
  14. Lab Invest. 2009 Dec;89(12):1410-22 - PubMed
  15. Cytotherapy. 2009;11(3):289-98, 1 p following 298 - PubMed
  16. Biochim Biophys Acta. 2013 Dec;1836(2):321-35 - PubMed
  17. Cytotherapy. 2006;8(4):315-7 - PubMed
  18. Plast Reconstr Surg. 2011 Apr;127(4):1467-77 - PubMed
  19. Hematology. 2002 Apr;7(2):113-7 - PubMed
  20. Cancer Biol Ther. 2008 Feb;7(2):245-51 - PubMed
  21. Blood. 2003 Nov 15;102(10):3837-44 - PubMed
  22. Cancer Res. 1992 Mar 15;52(6):1399-405 - PubMed
  23. J Transl Med. 2009 Jun 18;7:46 - PubMed
  24. J Craniofac Surg. 2008 Jan;19(1):204-10 - PubMed
  25. Stem Cell Rev. 2013 Feb;9(1):93-109 - PubMed
  26. Cell Transplant. 2012;21(7):1407-17 - PubMed
  27. Annu Rev Immunol. 1997;15:675-705 - PubMed
  28. Stem Cell Rev. 2014 Dec;10(6):830-40 - PubMed
  29. Nature. 2007 Oct 4;449(7162):557-63 - PubMed
  30. Invasion Metastasis. 1983;3(1):22-31 - PubMed
  31. Mol Med. 2011;17(7-8):579-87 - PubMed
  32. Int J Cancer. 2009 Sep 15;125(6):1276-84 - PubMed
  33. Exp Mol Med. 2013 Nov 15;45:e54 - PubMed
  34. Carcinogenesis. 2009 Apr;30(4):589-97 - PubMed
  35. Biol Cell. 2008 Apr;100(4):231-41 - PubMed

Publication Types